Clinical Trials Logo

Clinical Trial Details — Status: Recruiting

Administrative data

NCT number NCT06315595
Other study ID # 15-003511
Secondary ID NCI-2024-0189515
Status Recruiting
Phase
First received
Last updated
Start date September 30, 2015
Est. completion date September 30, 2030

Study information

Verified date March 2024
Source Mayo Clinic
Contact n/a
Is FDA regulated No
Health authority
Study type Observational

Clinical Trial Summary

This study evaluates contrast-enhanced MR angiography and contrast-enhanced MR perfusion imaging for the visualization of blood vessels and enhancing tissues with better spatial detail and improved temporal fidelity compared to current methods.


Description:

PRIMARY OBJECTIVE: I. To study how a variety of technological approaches in MRI can be used to provide improved performance contrast-enhanced MR imaging as used for angiography and perfusion. OUTLINE: This is an observational study. Participants are assigned to 1 of 3 groups. GROUP 1: Participants undergo magnetic resonance imaging (MRI) on study. Participants may also undergo blood sample collection on study. GROUP 2: Participants receive gadolinium based MR contrast agent intravenously (IV) and undergo MRI on study. Participants may also undergo blood sample collection on study. GROUP 3: Participants receive gadolinium based MR contrast agent IV and undergo up to two MRIs on study. Participants may also undergo blood sample collection on study.


Recruitment information / eligibility

Status Recruiting
Enrollment 300
Est. completion date September 30, 2030
Est. primary completion date September 30, 2030
Accepts healthy volunteers Accepts Healthy Volunteers
Gender All
Age group 18 Years and older
Eligibility Inclusion Criteria: - Adults Exclusion Criteria: - Standard exclusion criteria for clinical MRI; e.g. cardiac pacemaker, claustrophobia, an implanted device that has been determined to be MR conditional at 1.5T but not at 3T, anticipated considerable susceptibility artifact from hip prosthesis, etc.; previous rectal surgery which may preclude tolerance of an endorectal coil

Study Design


Related Conditions & MeSH terms


Intervention

Other:
Non-Interventional Study
Non-interventional study

Locations

Country Name City State
United States Mayo Clinic in Rochester Rochester Minnesota
United States Mayo Clinic in Arizona Scottsdale Arizona

Sponsors (3)

Lead Sponsor Collaborator
Mayo Clinic National Cancer Institute (NCI), National Institute for Biomedical Imaging and Bioengineering (NIBIB)

Country where clinical trial is conducted

United States, 

Outcome

Type Measure Description Time frame Safety issue
Primary Improved performance in contrast-enhanced magnetic resonance imaging (MRI) as used for angiography and perfusion Assessed by comparison of two images made from the raw data set but reconstructed using the standard vs. an alternative algorithm (to be determined during study). Data will be tabulated and analyzed statistically. Baseline (at enrollment); possible second scan at a later date
See also
  Status Clinical Trial Phase
Withdrawn NCT05191017 - Study of NUV-422 in Combination With Enzalutamide in Patients With mCRPC Phase 1/Phase 2
Completed NCT00255125 - Role of Soy Supplementation in Prostate Cancer Development Phase 3
Terminated NCT02809690 - 18F-FMAU PET/CT in Diagnosing and Characterizing Prostate Cancer Phase 1
Completed NCT06020287 - The Robot-Assisted Laparoscopic Radical Prostatectomy Combined Anterior and Posterior Approach
Recruiting NCT03572946 - Targeted Biopsy or Standard Biopsy for Clinical Significant Prostate Cancer Detection N/A
Active, not recruiting NCT03344757 - Health Gatherings - For Your Health After Cancer N/A
Recruiting NCT05137561 - Robotic-arm Assisted 68 Ga PSMA PET/CT Guided Prostate Biopsy Versus MR Directed TRUS Guided Prostate Biopsy N/A
Recruiting NCT04792138 - Learning MRI and Histology Image Mappings for Cancer Diagnosis and Prognosis.
Completed NCT03702439 - Prostate Cancer Screening Trial Using Imaging
Completed NCT04852224 - Strength, Aging, and Memory in Prostate Cancer
Completed NCT01240551 - F-18 Sodium Fluoride in Prostate Cancer Phase 2
Not yet recruiting NCT06430411 - Outcomes of Local Treatment for Oligometastatic Prostate Cancer Diagnosed Using PSMA PET Imaging: OLIGOMET Study
Recruiting NCT02436122 - Impact of Preoperative HbA1c Levels on Pathologic Features and Oncological Outcomes in the Patients With Prostate Cancer N/A
Active, not recruiting NCT03493945 - Phase I/II Study of Immunotherapy Combination BN-Brachyury Vaccine, M7824, N-803 and Epacadostat (QuEST1) Phase 1/Phase 2
Completed NCT04376008 - A Prospective Study Of Free-Hand Transperineal Image Fusion Targeted Biopsies Under Local Anesthesia N/A
Recruiting NCT05252390 - NUV-868 as Monotherapy and in Combination With Olaparib or Enzalutamide in Adult Patients With Advanced Solid Tumors Phase 1/Phase 2
Recruiting NCT06292897 - Using Tissue-based Spatial Data to Understand How Obesity-related Tumor Metabolites Fuel Prostate Cancer Progression
Recruiting NCT03819751 - MRI-targeted Biopsy of the Prostate: Software Versus Visual Registration in the Accuracy of Prostate Cancer Detection N/A
Not yet recruiting NCT05460312 - Protein Kinase A in Prostate Cancer Tissue.
Completed NCT00005916 - PSA-Based Vaccine and Radiotherapy to Treat Localized Prostate Cancer Phase 2